HSNOHbio integrates artificial intelligence, computational chemistry, and structural neuroscience to design next-generation CNS therapeutic candidates.
AMPA receptors play essential roles in excitatory neurotransmission, synaptic plasticity, learning, and memory.
Conventional approaches targeting highly conserved receptor regions may encounter challenges in achieving subtype selectivity.
HSNOHbio investigates structurally distinctive allosteric regions of the GluA3 AMPA receptor as potential opportunities for selective pharmacological modulation.
G3-01EG is a computationally designed small molecule being investigated as a potential GluA3-selective positive allosteric modulator (PAM).
Its proposed binding mechanism and functional activity remain subject to experimental confirmation.
AI-assisted molecular design
Structure-based virtual screening
Molecular docking and binding-site analysis
Computational ADME and blood-brain barrier property assessment
Receptor subtype selectivity optimization
Experimental binding and electrophysiological validation
Our research strategy emphasizes receptor subtype selectivity, novel allosteric mechanisms, and rational molecular optimization to support future CNS drug development.